Replies to post #175781 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Only Trials Results Matter

...the trials have to proceed,....

Honestly, the postings on this message board cannot in any substantive way control what either retail or institutional investors decide to pay for shares of AVXL. For the few who follow the postings of the regulars here, our pronouncements are understood to be, at best, tangential.

The only thing that really matters will be the ability of Anavex Life Sciences Corp to sell any of their proposed drugs somewhere in the world. Presently not possible. No regulatory authorization for such; awaiting affirmative clinical trials results. Results will appear in 2019, confirming and denying any and all of the corporate and science assessment postings that have appeared here.

I fully expect results to be very positive; for all three central nervous system conditions being tested: Rett syndrome (on the basis of very positive mice-with-Rett trials); Parkinson’s dementia; and Alzheimer’s dementia, because of the ability of Anavex 2-73 to restore normalized neuron homeostasis (as shown in a multitude of murine studies).

But, will all of that happen? A number of frequent posters claim that it can’t or won’t. I and others believe it will. But until sufficient clinical results appear, contentions of Anavex success or failure are merely clinically-unsubstantiated conjectures.

Henceforth, my postings should be distant and infrequent, at best; until results appear. Until then, I will have little to usefully contribute. I have no compulsion, interest, or purpose in trying to persuade readers to my very positive outlook. We are all grown-ups here, making our own personal investment decisions.

My best wishes to all.

Indeed, let the trials begin!

[nidan7500]

the trials have to proceed, which we believe is happening "as planned."

tradeher...Both falconer and Biotechclubs posts were important for at least a couple of reasons. First of all they added detail and summarized technical facts supporting the foundation on which A2-73 CNS cellular homeostasis claims are based. IMO, they accomplished this w/o a lot of hysteria and arm waving by using rational, fact based processing. Secondly, at some point we must trust that the body of knowledge fairly presented continues to support Dr. M's. uncontradicted thesis.

IMO, this kind of process is what Precision Medicine FDA initiative are intended to demonstrate. Yes, we await the verification trials as evidence of closure making the distinction from the old days of discovery by trial and error. This is not the end since this is all about learning, but, these trials are the end of the beginning. These folks w/Anavex SAB have defined the interface-threshold for learning which is the boundary between what we know and what we know we do not know (Senge). That is the interface at which learning occurs. Intuition suggests We are a long way from being done. Believe it or not, we had to go through this else CNS diseases would stalk our garndchildren as well.